简体
简体中文
繁體中文

Harbor Osmosis新兴市场资源高效率主动型ETF EFFE

已收盘 07-02 16:00:00 美东时间

26.9394

-0.041

-0.15%

华盛通华盛通
立即下载
  • 最 高26.9394
  • 今 开26.9804
  • 成交量 16股
  • 最 低 26.9394
  • 昨 收 26.9804
  • 总市值 1.39亿
  • 52周最高 30.05
  • 市盈率 --
  • 换手率 0.00%
  • 52周最低 21.557
  • 委 比 0.00%
  • 总股本 517.50万
  • 历史最高 30.05
  • 量 比 0
  • 振 幅 0.00%
  • 历史最低 17.2403
  • 每 手 1
  • 风险率 1.88%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • BRIEF-Sadot Group Sells Sadot Latam To Dream America Marketing Services

    BRIEF-Sadot Group Sells Sadot Latam To Dream America Marketing Services June 30 (Reuters) - Sadot Group Inc SDOT.O : ENTERS SHARE PURCHASE AGREEMENT WITH DREAM AMERICA MARKETING SERVICES ON JUNE 26, 2026 - SEC FILING TO CEASE CONSOLIDATION OF SADOT LATAM IN FINANCIAL STATEMENTS FROM CLOSING DATE - S

    06-30 18:28

  • BRIEF-EMA Recommends Revoking Marketing Authorisation For Tavneos In EU

    BRIEF-EMA Recommends Revoking Marketing Authorisation For Tavneos In EU June 26 (Reuters) - EMA: EMA - RECOMMENDS REVOKING MARKETING AUTHORISATION FOR TAVNEOS IN THE EU EMA - REVIEW OF TAVNEOS INITIATED OVER DATA INTEGRITY CONCERNS IN ADVOCATE STUDY EMA - FINDS ADVOCATE STUDY FOR TAVNEOS BREACHED GO

    06-26 18:50

  • BRIEF-Rocky Mountain Chocolate Factory - Jeffrey R Geygan Resigns As Interim CEO Effective June 26, 2026 - SEC Filing

    BRIEF-Rocky Mountain Chocolate Factory - Jeffrey R Geygan Resigns As Interim CEO Effective June 26, 2026 - SEC Filing June 26 (Reuters) - Rocky Mountain Chocolate Factory Inc (Delaware) RMCF.O : ROCKY MOUNTAIN CHOCOLATE FACTORY - JEFFREY R GEYGAN RESIGNS AS INTERIM CEO EFFECTIVE JUNE 26, 2026 - SEC

    06-26 18:09

  • BRIEF-Align Technology Announces Board Leadership Transition. C. Raymond Larkin, Jr. To Retire As Chairman

    BRIEF-Align Technology Announces Board Leadership Transition. C. Raymond Larkin, Jr. To Retire As Chairman June 18 (Reuters) - Align Technology Inc ALGN.O : ALIGN TECHNOLOGY ANNOUNCES BOARD LEADERSHIP TRANSITION. C. RAYMOND LARKIN, JR. TO RETIRE AS CHAIRMAN AND KEVIN CONROY TO BE APPOINTED CHAIRMAN

    06-19 09:03

  • BRIEF-Aegon Appoints Will Fuller As President And COO Effective January 2027

    BRIEF-Aegon Appoints Will Fuller As President And COO Effective January 2027 June 17 (Reuters) - Aegon Ltd AEGN.AS : AEGON STRENGTHENS LEADERSHIP TEAM AND SELECTS NEW YORK AS LOCATION FOR ITS FUTURE HEADQUARTERS APPOINTS WILL FULLER AS PRESIDENT AND COO EFFECTIVE JANUARY 1, 2027 Source text: ID:nGNX

    06-17 14:02

  • BRIEF-Summit Hotel Properties Announces Management Transition

    BRIEF-Summit Hotel Properties Announces Management Transition June 12 (Reuters) - Summit Hotel Properties Inc INN.N : SUMMIT HOTEL PROPERTIES ANNOUNCES MANAGEMENT TRANSITION SUMMIT HOTEL PROPERTIES - CFO WILLIAM ("TREY") CONKLING TO DEPART EFFECTIVE JUNE 15, 2026 SUMMIT HOTEL PROPERTIES - PRESIDENT

    06-12 18:32

  • BRIEF-Medallion Bank Announces CEO Transition

    BRIEF-Medallion Bank Announces CEO Transition June 12 (Reuters) - Medallion Bank MBNKO.O : MEDALLION BANK ANNOUNCES CEO TRANSITION MEDALLION BANK - DONALD POULTON TO RETIRE AS CEO EFFECTIVE JUNE 30, 2026 MEDALLION BANK - JUSTIN HALEY TO BECOME CEO EFFECTIVE JULY 1, 2026 Source text: ID:nGNX1DVPDz Fu

    06-12 18:31

  • BRIEF-Rocket Lab - Nasdaq-100 Inclusion Effective June 22, 2026

    BRIEF-Rocket Lab - Nasdaq-100 Inclusion Effective June 22, 2026 June 12 (Reuters) - Rocket Lab Corp RKLB.O : ROCKET LAB - NASDAQ-100 INCLUSION EFFECTIVE JUNE 22, 2026 Source text: ID:nGNX5V28rr Further company coverage: RKLB.O (( Reuters.Briefs@thomsonreuters.com ;))

    06-12 18:02

  • BRIEF-Bmgl To Effect Reverse Share Split On June 22, 2026

    BRIEF-Bmgl To Effect Reverse Share Split On June 22, 2026 June 10 (Reuters) - Basel Medical Group Ltd BMGL.O : BMGL TO EFFECT REVERSE SHARE SPLIT ON JUNE 22, 2026 BASEL MEDICAL GROUP - BOARD APPROVES 1-FOR-12 REVERSE SHARE SPLIT EFFECTIVE JUNE 22, 2026 Source text: ID:nGNX6ZW8R7 Further company cove

    06-10 19:00

  • FOCUS-Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon

    FOCUS-Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon Tolerability remains key challenge, with most GLP-1 drugs causing significant side effects Lilly's retatrutide trial data confirms highest weight loss among current and pipeline drugs Shares of Lilly rose after ADA conferen

    06-10 18:00